Scientific Programme
Course Directors
R. De Caterina (IT), S.D. Kristensen (DK)
Speakers
G. Agnelli (IT), P. Amarenco (FR), J.P. Collet (FR), E. Grove (DK), K. Huber (AT), S.E. Husted (DK), D.J. Moliterno (US), J. Morais (PT), F.J. Neumann (DE), H. Schühlen (DE), R. Storey (UK), F.W.A. Verheugt (NL), M. Zimarino (IT)
Programme
Thursday 22 May
12:30-14:00: Lunch
SESSION 1: PATHOPHYSIOLOGY AND METHODOLOGY
Chairpersons: R. De Caterina and S.D. Kristensen
14:00-14:20 Atherothrombosis and arterial thromboembolism: update on pathophysiological background – R. De Caterina
14:20-14:40 Platelets - monitoring and ‘resistance’ to antiplatelet agents – S.D. Kristensen
14:40-14:50 Overall Discussion
SESSION 2: UPDATE IN ORAL PLATELET INHIBITORS
Chairpersons: S. Husted and F.W.A. Verheugt
14:50-15:10 Low-dose aspirin, coxibs, non-steroidal anti-inflammatory drugs, and the need for proton pump inhibitors – R. Storey
Debate: oral P2Y12 inhibitors: what should we use?
15:10-15:20 Clopidogrel – E. Grove
15:20-15:30 Prasugrel – J-P. Collet
15:30-15:40 Ticagrelor – R. Storey
15:40-16:00 Discussion
16:00-16:15 New antiplatelet drugs: cangrelor, elinogrel, thrombin receptor antagonists and other newcomers – D.J. Moliterno
16:15-16:30 Overall Discussion
16:30-17:00 Coffee Break
SESSION 3: Case Presentations - Difficult scenarios in anti-thrombotic therapy
(15 min presentations + 15 min discussion for each case)
Chairpersons: E. Grove and M. Zimarino
17:00-17:30: Case 1: Stroke and recurrent left atrial appendage thrombus in a patient with atrial fibrillation under old and new oral anticoagulants – M. Rohla
17:30-18:00: Case 2 : Risk-Adjusted Strategies in Patients with Acute Pulmonary Embolism - M. Lankeit
18:00-18:30: Case 3: A case for an individualized antiplatelet regimen to prevent stent thrombosis – P. Capranzano
Friday 23 May
Chairperson: D.J. Moliterno
9:00-9:20 Bivalirudin vs heparins during percutaneous interventions in acute coronary syndromes – D.J. Moliterno
9:20-9:40 GP IIb/IIIa antagonists: still needed? – S.D. Kristensen
9:40-10:00 Coronary interventions 2014: New generation of stents and intracoronary drug delivery – J.-P. Collet
10:00-10:20 Stent thrombosis with bare metal and drug-eluting stents and biovascular scaffolding devices - F.J. Neumann
10:20-10:30 – Overall Discussion
10:30-11:00 Coffee break
SESSION 4: STABLE CORONARY HEART DISEASE
Chairpersons: R. Storey and K. Huber
Debate: PCI for stable CHD patients
11:00-11:15 PCI for stable patients is not needed – F.W.A. Verheugt
11:15-11:30 PCI for stable patients is still needed – H. Schühlen
11:30-11.45 Chronic anti-thrombotic therapy for a chronic disease: is aspirin still needed – F.W.A. Verheugt
11:45-12:00 Complete versus incomplete revascularization – M. Zimarino
12:00-12:10 Overall Discussion The mission of the ESC: "To reduce the burden of cardiovascular disease in Europe."
SESSION 5: NON-ST ELEVATION ACUTE CORONARY SYNDROMES
Chairs: R. Storey and H. Schühlen
12:10-12:25 Markers for risk stratification: why and what? – S. Husted
12:25-12:40 Preventing bleeding to prevent ischemia and death – J. Morais
12:40-12:55 Optimal timing for PCI – H. Schühlen
12:55-13:10 Discussion
13:10-14:00 Lunch
SESSION 6: ACUTE ST-ELEVATION MYOCARDIAL INFARCTION
Chairperson: R. De Caterina and F.J. Neumann
14:00-14:15 Pre-hospital thrombolysis: why to keep it as an option in organizational models – K. Huber
14:15-14:30 Combining different treatment option for cath lab therapy in STEMI – F.J. Neumann
14:30-15:00 Dialogue: Primary PCI – tips and tricks - 4 key debate questions – H. Schühlen and S.D. Kristensen
15:00-15:15 New oral anticoagulants in acute coronary syndromes – R. De Caterina
15:15-15:45 Overall Discussion
15:45-16:00 Coffee Break
Session 7: Venous thromboembolism: new drugs and duration of anticoagulant therapy
Chairpersons: J. Morais and F.W.A. Verheugt
16:00-16:15 Aspirin and traditional anticoagulation in venous thromboembolism. G. Agnelli
16:15-16:30 Dabigatran etexilate, rivaroxaban, apixaban, edoxaban: compared pharmacology - S. Husted
16:30 -17:00 The new anticoagulants in venous thromboembolism: new trials and duration of therapy. G. Agnelli
Saturday May 24
SESSION 8: ATRIAL FIBRILLATION
Chairpersons: D.J. Moliterno and S. Husted
09:00-09:20 Risk assessment: use of warfarin, aspirin and clopidogrel - J. Morais
09:20-09:40 New anticoagulants in atrial fibrillation: comparative clinical results – R. De Caterina
0940:10:00 Which anticoagulant for which atrial fibrillation patient? P. Amarenco
10:00-10:30: Round table and overall discussion
10:30-11:00 Coffee Break
SESSION 9: MISCELLANEOUS
Chairpersons: K. Huber and J. P. Collet
11:00-11:30: Secondary prevention of ischemic and hemorrhagic stroke in atrial fibrillation – P. Amarenco
11:30-11:50 Triple anti-thrombotic therapy with aspirin, P2Y12 inhibitors and vitamin K antagonists/new anticoagulants: rationale and risk – K. Huber
11:50-12:00 Concluding remarks – S.D. Kristensen and R. De Caterina
This educational course has been supported by AstraZeneca, Boehringer Ingelheim, Bristol-Myers Squibb and Daiichi-Sankyo Lilly, in the form of unrestricted educational grants.
The scientific programme has not been influenced in any way by its sponsors.
Our mission: To reduce the burden of cardiovascular disease.